Navigation Links
Open Wide, It's Time to Lose Weight!
Date:1/5/2009

GRAND RAPIDS, Mich., Jan. 5 /PRNewswire/ -- Sentinel Group announced the first implants of the Full Sense(TM) Device on November 3-4, 2008 at Galenia Hospital in Cancun, Mexico by American doctors Randal Baker MD, James Foote MD and Mexican doctor Jorge Trevino MD.

The Full Sense Device is a stent like device placed through the mouth into the top of the stomach to cause a feeling of fullness. It causes fullness by placing pressure on the bottom of the esophagus and the top of the stomach. The device can be placed and removed via endoscopy. "The Full Sense Device essentially tricks the brain into thinking that the stomach is full when it is not," said Fred Walburn, PhD., President of Sentinel Group. "This technology represents potentially the greatest step forward in the battle against obesity since the inception of bariatric surgery."

"Most of today's bariatric surgeries require some type of pouch filled with food to create a full feeling," stated Randal Baker MD. "This device, so far, is showing better weight loss than most surgeries because it does not depend on food intake." Dr. Foote adds, "We believe this technology will be another great tool in the fight against obesity."

"Galenia Hospital is pleased to be the first center to treat patients with the Full Sense Device," said Dr. Trevino, Head of Bariatric Surgery. "The patients are losing weight better than most of my surgery patients and are extremely happy."

ABOUT GALENIA

The Galenia Hospital located in Cancun, Quintana Roo, Mexico is a modern facility with state of the art equipment which go beyond the everyday services, with highly trained doctors and a wide range of medical specialties along with experienced people working for health care of national and international patients.

ABOUT SENTINEL GROUP

Sentinel Group is a medical device development company founded to commercialize patents owned by its principals and to assist physician inventors in commercializing their ideas. The company's intellectual property portfolio includes technologies in the areas of: bariatrics, colorectal anastomoses, diverticulitis, hiatal hernia, depression, Natural Orifice Translumenal Endoscopic Surgery (NOTES), Endoscopy and GERD. The Company's first product is the Full Sense(TM) Bariatric Device.

The Full Sense(TM) Device is not available in all markets pending regulatory clearance. Sentinel Group(R) and Full Sense(TM) Device are trademarks of Sentinel Group LLC.


'/>"/>
SOURCE Sentinel Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. 3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc.
2. Minneapolis Hosts National Conference on Tobacco or Health October 24-26 on Heels of Minnesotas Statewide, Smoke-Free Law
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... 2017 , ... Elisabete Miranda, president and CEO of ... magazine as one of its 2017 Enterprising Women of the Year, a prestigious ... that they have fast-growth businesses, mentor or actively support other women and girls ...
(Date:4/26/2017)... NJ (PRWEB) , ... April 26, 2017 , ... RawTrition ... an easy way to get nutrients from SUPERFOODS! , RawTrition is taking ... at the cellular level because the body recognizes its raw form (unlike the synthetically ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition Duchenne, ... Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on ... clinical trial in Duchenne announced today. , Coalition Duchenne funded studies carried ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: